Company: PTPI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001410578-25-001349
Chunk: 2

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1F
Chunk 2
---
ITEM 1. UNAUDITED FINANCIAL STATEMENTS.

PETROS PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

​

​​​​​​​​​March 31, ​December 31, ​    2025    2024Assets ​   ​  Current assets: ​   ​  Cash and cash equivalents​$ 8,931,054​$ 1,718,645Prepaid expenses and other current assets​  53,405​  885Current assets held for sale​​ 5,481,187​​ 5,574,748Total current assets​  14,465,646​  7,294,278​​​ ​​​ ​Non-current assets held for sale​​ 3,139,720​​ 3,341,032Total assets​$ 17,605,366​$ 10,635,310​​​​​​​Liabilities, Convertible Redeemable Preferred Stock and Stockholders’ Deficit ​ ​​   Current liabilities:​ ​​   Accounts payable​​ 756,703​​ 764,333Accrued expenses​  199,703​  99,641Accrued Series A Convertible Preferred payments payable​  1,846,142​  1,909,496Warrant Liability​  8,292,000​  —Current liabilities held for sale​​ 16,037,436​​ 15,254,195Total current liabilities​  27,131,984​  18,027,665​​​​​​​Non-current liabilities held for sale​  57,590​ ​ 75,223Total liabilities​  27,189,574​ ​ 18,102,888​​​​​​​Commitments and contingencies (see note 9)​​​​​​Series A convertible redeemable preferred stock (par value $0.0001 per share and $1,000 stated value), 15,000 and 15,000 shares authorized at March 31, 2025, and December 31, 2024, respectively; 0 and 0 shares issued and outstanding at March 31, 2025, and December 31, 2024, respectively​​ —​​ —​​​​​​​Stockholders’ Deficit:​  ​​   Series B convertible redeemable preferred stock (par value